Atezolizumab In Metastatic Tnbc: Long-Term Clinical Outcomes And Biomarker Analyses

Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses

IMpassion130: results of atezolizumab plus nab-paclitaxel for frontline TNBC

Triple Negative Breast Cancer: Predictive and Prognostic Biomarkers for Neo/Adjuvant Therapy

Total Health | Oncology

ALICE: atezolizumab + immunogenic chemotherapy in metastatic TNBC

Dr. Kalinsky on Clinical Impact of Atezolizumab Combo in TNBC

PD-L1 and TMB as biomarkers in the IMvigor211 trial of atezolizumab vs. chemo for bladder cancer

Neelima Denduluri, MD -- Treatment of Triple Negative Breast Cancer

Mitchell Cancer Institute

IMpassion130 Data Demonstrate Clinical Benefit for Immunotherapy in Metastatic TNBC

Targeted Oncology

IMPassion130: atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naiv...

IMpassion130: immunotherapy for TNBC

Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast Cancer

Dana-Farber Cancer Institute

Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

Case 3: Atezolizumab/Nab-Paclitaxel for Triple Negative Breast Cancer

Targeted Oncology

IMpassion130 Trial: OS Updates in Metastatic TNBC

Atezolizumab Plus Nab-Paclitaxel for Advanced Triple Negative Breast Cancer

Phase II Results for Pembrolizumab Monotherapy in Metastatic TNBC

Targeted Oncology

Five-Year Dosing, Efficacy Results for Nab-Paclitaxel in TNBC

Targeted Oncology

Dr. Nanda on Immunotherapy in Metastatic TNBC

Dr. Saeed Rafii on Atezolizumab/ Nab-paclitaxel in TNBC

ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC

European Society for Medical Oncology (ESMO)